13.3
Impact Factor
23.90
CiteScore
< 5 days
First Decision
Theranostics 2017; 7(3):562-572. doi:10.7150/thno.16895 This issue Cite
Research Paper
1. Molecular Imaging & Therapy Branch, Division of Precision Medicine, National Cancer Center, Goyang, Korea;
2. Dept. of Radiology, Seoul National University Hospital, Seoul, Korea
Perfluorocarbon nanoemulsions (PFCNEs) have recently been undergoing rigorous study to investigate their ability to improve the therapeutic efficacy of tumor ablation by high intensity focused ultrasound (HIFU). For precise control of PFCNE delivery and thermal ablation, their accumulation and distribution in a tumor should be quantitatively analyzed. Here, we used fluorine-19 (19F) magnetic resonance imaging (MRI) to quantitatively track PFCNE accumulation in a tumor, and analyzed how intra-tumoral PFCNE quantities affect the therapeutic efficacy of HIFU treatment. Ablation outcomes were assessed by intra-voxel incoherent motion analysis and bioluminescent imaging up to 14 days after the procedure. Assessment of PFCNE delivery and treatment outcomes showed that 2-3 mg/mL of PFCNE in a tumor produces the largest ablation volume under the same HIFU insonation conditions. Histology showed varying degrees of necrosis depending on the amount of PFCNE delivered. 19F MRI promises to be a valuable platform for precisely guiding PFCNE-enhanced HIFU ablation of tumors.
Keywords: Perfluorocarbon nanoemulsion (PFCNE), 19F MRI, High Intensity Focused Ultrasound (HIFU), Tumor Ablation, Diffusion MR